[go: up one dir, main page]

WO2007103261A3 - Compositions immunogènes epha2 à base de la listeria - Google Patents

Compositions immunogènes epha2 à base de la listeria Download PDF

Info

Publication number
WO2007103261A3
WO2007103261A3 PCT/US2007/005512 US2007005512W WO2007103261A3 WO 2007103261 A3 WO2007103261 A3 WO 2007103261A3 US 2007005512 W US2007005512 W US 2007005512W WO 2007103261 A3 WO2007103261 A3 WO 2007103261A3
Authority
WO
WIPO (PCT)
Prior art keywords
listeria
immunogenic compositions
epha2
present
constructs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/005512
Other languages
English (en)
Other versions
WO2007103261A2 (fr
Inventor
Elizabeth Bruckheimer
Michael S Kinch
Peter A Kiener
Thomas W Dubensky Jr
David N Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Cerus Corp
Original Assignee
MedImmune LLC
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC, Cerus Corp filed Critical MedImmune LLC
Priority to PCT/US2007/005512 priority Critical patent/WO2007103261A2/fr
Publication of WO2007103261A2 publication Critical patent/WO2007103261A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007103261A3 publication Critical patent/WO2007103261A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des acides nucléiques de synthèse comprenant une séquence nucléotide codante pour un peptide antigène EphA2 et la Listeria contenant de tels produits de synthèse. L'invention concerne notamment la Listeria génétiquement modifiée pour exprimer une pluralité de peptides antigéniques EphA2 et des compositions immunogènes contenant une telle Listeria. L'invention concerne, inter alia, l'utilisation des compositions immunogènes pour déclencher une réponse immunitaire contre une cellule d'expression de EphA2 ainsi que pour traiter, gérer et/ou prévenir un trouble et/ou une maladie à hyperprolifération impliquant l'angiogénèse aberrante.
PCT/US2007/005512 2006-03-01 2007-03-01 Compositions immunogènes epha2 à base de la listeria Ceased WO2007103261A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2007/005512 WO2007103261A2 (fr) 2006-03-01 2007-03-01 Compositions immunogènes epha2 à base de la listeria

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/778,426 2006-03-01
PCT/US2007/005512 WO2007103261A2 (fr) 2006-03-01 2007-03-01 Compositions immunogènes epha2 à base de la listeria

Publications (2)

Publication Number Publication Date
WO2007103261A2 WO2007103261A2 (fr) 2007-09-13
WO2007103261A3 true WO2007103261A3 (fr) 2008-12-04

Family

ID=38475444

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/005512 Ceased WO2007103261A2 (fr) 2006-03-01 2007-03-01 Compositions immunogènes epha2 à base de la listeria

Country Status (1)

Country Link
WO (1) WO2007103261A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
CA2791905A1 (fr) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarqueurs pour theranostique
BR112012025593A2 (pt) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings biomarcadores em circulação para doença
SG11201901979SA (en) 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN112533939B (zh) * 2018-08-02 2024-03-19 苏州若泰医药科技有限公司 一种基于减毒李斯特菌激活的抗原提呈细胞的肿瘤免疫治疗组合物、制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037233A2 (fr) * 2003-10-15 2005-04-28 Medimmune, Inc. Vaccins epha2 a base de listeria

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037233A2 (fr) * 2003-10-15 2005-04-28 Medimmune, Inc. Vaccins epha2 a base de listeria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOODY G.E. ET AL.: "Recombinant Listeria monocytogenes-based immunotherapy targeting the Receptor Tyrosine Kinase EphA2", PROC. AMER. ASSOC. CANCER RES., vol. 45, 2004, pages 504, XP002449204 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096963B2 (en) 2015-06-26 2021-08-24 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
US10799533B2 (en) 2015-10-23 2020-10-13 Cerus Corporation Plasma compositions and methods of use thereof
US12282015B2 (en) 2016-12-23 2025-04-22 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US12064537B2 (en) 2017-03-03 2024-08-20 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
US11554185B2 (en) 2017-12-29 2023-01-17 Cerus Corporation Systems and methods for treating biological fluids
US12214092B2 (en) 2017-12-29 2025-02-04 Cerus Corporation Systems and methods for treating biological fluids
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
US11883544B2 (en) 2019-06-28 2024-01-30 Cerus Corporation System and methods for implementing a biological fluid treatment device
US12343436B2 (en) 2019-06-28 2025-07-01 Cerus Corporation System and methods for implementing a biological fluid treatment device

Also Published As

Publication number Publication date
WO2007103261A2 (fr) 2007-09-13

Similar Documents

Publication Publication Date Title
WO2007103261A3 (fr) Compositions immunogènes epha2 à base de la listeria
WO2012106377A3 (fr) Molécules d'acide nucléique codant de nouveaux antigènes d'herpès, vaccin les comprenant et procédés pour les utiliser
WO2013006756A3 (fr) Variants d'alpha-amylase et polynucléotides codant ces variants
WO2012038061A3 (fr) Nanocapsules contenant des microémulsions
MX2013002591A (es) Canalrodopsina 2 mutante.
WO2011094358A9 (fr) Molécules d'acide nucléique de grippe et vaccins préparés à partir de celles-ci
EP4253534A3 (fr) Variants d'alpha-amylase et polynucléotides les codant
WO2007062656A3 (fr) Vaccin nucléotidique
WO2010019262A3 (fr) Vaccin polyvalent
WO2012051327A3 (fr) Procédé de recombinaison à double adaptateur pour la concaténation efficace de multiples fragments d'adn dans des arrangements de recombinaison aléatoire ou spécifiée
AR079881A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
WO2012146171A9 (fr) Polypeptides capables de favoriser l'activité cellulolytique et polynucléotides codant pour ceux-ci
WO2011035027A3 (fr) Polypeptides ayant une activité cellulolytique améliorée et polynucléotides codant pour ceux-ci
WO2011005867A8 (fr) Polypeptides ayant une activité cellulolytique améliorée et polynucléotides codant pour ceux-ci
IL213039A (en) Human anti-angiopoietin-2 antibodies, pharmacological compounds containing these antibodies, their nucleic acids encoded, and expression vectors
WO2011020783A3 (fr) Immunoconjugués ciblés
WO2013063383A3 (fr) Vecteurs codant pour un facteur de viabilité des cônes dérivé des bâtonnets
MX343048B (es) Oligodesoxinucleotidos inmunoestimulantes.
WO2010039224A3 (fr) Séquences du virus syncytial respiratoire (rsv) destinées à l'expression de protéines et aux vaccins
WO2010135836A8 (fr) Nouvelles enzymes bêta-glucosidases
WO2013119302A3 (fr) Variants du polypeptide gh61 et polynucléotides codant pour ceux-ci
EP3211074A3 (fr) Variantes de la lipase et polynucléotides les codant
MX2015001542A (es) Metodo.
IN2015DN03206A (fr)
WO2014017493A9 (fr) Vaccin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07752226

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07752226

Country of ref document: EP

Kind code of ref document: A2